Evidence map›Paper›PMID 27573037›Full record

ArticleMolecular medicine reports2016

Severity of pancreatitis‑associated intestinal mucosal barrier injury is reduced following treatment with the NADPH oxidase inhibitor apocynin.

Wenhong Deng, Ablikim Abliz, Sheng Xu, Rongze Sun, Wenyi Guo, Qiao Shi, Jia Yu, Weixing Wang

Open access · hybridAbstract read
In one paragraph

Article in Molecular medicine reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Annals of translational medicine · 2021
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Wenhong DengDepartment of General Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China.
Ablikim AblizDepartment of General Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China.
Sheng XuDepartment of General Surgery, People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi 530021, P.R. China.
Rongze SunDepartment of General Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China.
Wenyi GuoDepartment of General Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China.
Qiao ShiDepartment of General Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China.
Jia YuDepartment of General Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China.
Weixing WangDepartment of General Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China.
Wuhan University · CNRenmin Hospital of Wuhan University · CNThe People's Hospital of Guangxi Zhuang Autonomous Region · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent studies demonstrated that apocynin, a nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX) inhibitor, significantly decreased acute pancreatitis‑associated inflammatory and oxidative stress parameters. In addition, apocynin was able to reduce ischemic reperfusion injury‑associated damage; however, the exact effects of apocynin on acute pancreatitis‑associated intestinal mucosal injury have yet to be fully clarified. The present study aimed to investigate the protective effects of apocynin on intestinal mucosal injury in a rat model of severe acute pancreatitis (SAP). A total of 60 male Sprague Dawley rats were randomly divided into four groups (n=15/group): Sham operation group (SO), SAP group, apocynin treatment (APO) group and drug control (APO‑CON) group. SAP was induced by retrograde injection of 5% sodium taurocholate into the biliopancreatic duct. Apocynin was administered 30 min prior to SAP induction in the APO group. All rats were sacrificed 12 h after SAP induction. Intestinal integrity was assessed by measuring diamine oxidase (DAO) levels. Morphological alterations to intestinal tissue were determined under light and transmission electron microscopy. NOX2, p38 mitogen‑activated protein kinases (MAPK) and nuclear factor (NF)‑κB expression levels were detected in the intestine by immunohistochemical staining. Oxidative stress was detected by measuring intestinal malondialdehyde (MDA) and superoxide dismutase content. In addition, blood inflammatory cytokines, and amylase (AMY) and lipase (LIP) levels were evaluated. The results demonstrated that apocynin attenuated the following: i) Serum AMY, LIP and DAO levels; ii) pancreatic and intestinal pathological injury; iii) intestinal MDA content; iv) intestinal ultrastructural alterations; v) serum interleukin (IL)‑1β, IL‑6 and tumor necrosis factor (TNF)‑α levels; and vi) NOX2, p38 MAPK and NF‑κB expression in intestinal tissues. These results suggested that apocynin may attenuate intestinal barrier dysfunction in sodium taurocholate‑induced SAP, presumably via its role in the prevention of reactive oxygen species generation and inhibition of p38 MAPK and NF‑κB pathway activation. These findings provide novel insight suggesting that pharmacological inhibition of NOX by apocynin may be considered a novel therapeutic method for the treatment of intestinal injury in SAP.

Indexed as

AcetophenonesAnimalsAnti-Inflammatory Agents, Non-SteroidalAntioxidantsCytokinesEnzyme InhibitorsIntestinal MucosaMaleNADPH OxidasesNF-kappa BOxidative Stressp38 Mitogen-Activated Protein KinasesPancreasPancreatitisRats, Sprague-DawleyAcetophenonesacetovanilloneAnti-Inflammatory Agents, Non-SteroidalAntioxidantsCytokinesEnzyme InhibitorsNADPH OxidasesNF-kappa Bp38 Mitogen-Activated Protein Kinases

Identifiers

PMID27573037
PMCPMC5042780
OpenAlexW2511863915

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.